Clinical characteristics and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: A final report of CML Cooperative Study Group.
文献摘要
In this study, we investigated the clinical characteristics and outcomes of therapy‑related chronic myeloid leukemia (TR‑CML), defined as CML arising after prior chemotherapy or radiotherapy for a preceding malignancy. Among 819 eligible patients, 33 (4%) were identified as having TR‑CML. The median interval from the initiation of prior therapy to the onset of CML was 6 years (range, 1.2-33). Compared with patients with de novo CML, those with TR‑CML were older and had lower white blood cell counts and smaller spleen size at diagnosis. Other factors, including sex, disease stage, transcript type, clonal cytogenetic abnormalities in Ph‑positive cells, hematologic parameters, and ELTS risk, did not differ between the groups. The cumulative deep molecular response rate was slightly lower in the TR‑CML group (p = 0.054), whereas the major molecular response rate was comparable between the groups (p = 0.95). No significant differences were observed in overall survival (p = 0.22), CML‑related death (p = 0.70), or progression‑free survival (p = 0.27). However, event‑free survival was significantly worse in the TR‑CML group (p = 0.037), primarily due to more frequent loss of response or disease progression. In conclusion, TR‑CML may represent an adverse clinical entity in the era of tyrosine kinase inhibitors. Further studies incorporating molecular and genomic analyses are warranted to determine whether TR‑CML constitutes a biologically distinct subtype.